Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 4/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.34 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.34 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 8/20 | 0.32 |
| ▸ | MRE11 | P49959 | 1/20 | 0.32 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5585762 | 0.89 | FFAR1 (0.38) | FFAR1ALOX5HRH3ADRB1ADRB3 | |
| SCHEMBL5585863 | 0.84 | FFAR1 (0.36) | FFAR1ALOX5HRH3ADRB1ADRB3 | |
| SCHEMBL5585457 | 0.83 | FFAR1 (0.44) | FFAR1ALOX5HRH3PTPN2PTPN1 | |
| SCHEMBL5585524 | 0.83 | FFAR1 (0.44) | FFAR1ALOX5HRH3PTPN2PTPN1 | |
| SCHEMBL5585482 | 0.82 | FFAR1 (0.35) | FFAR1ALOX5HRH3ADRB1ADRB3 | |
| SCHEMBL5585522 | 0.82 | FFAR1 (0.42) | FFAR1ALOX5HRH3PTPN2PTPN1 | |
| SCHEMBL5585637 | 0.80 | HDAC3 (0.43) | — | |
| SCHEMBL5585783 | 0.75 | MRGPRX4 (0.39) | FFAR1ALOX5HRH3PTPN1 | |
| SCHEMBL5585571 | 0.73 | HRH3 (0.44) | FFAR1ALOX5HRH3PTPN1ENPP2 | |
| SCHEMBL6000173 | 0.73 | HRH3 (0.44) | FFAR1ALOX5HRH3PTPN1ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7163952-B2 | Azole compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2007-01-16 | — | — | US | disclosed |
| US-7163952-B2 | Azole compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2007-01-16 | — | — | US | disclosed |
| US-20050065196-A1 | Azole compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2005-03-24 | — | — | US | disclosed |
| EP-1452530-A1 | AZOLE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2004-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065196-A1 | Azole compound and medicinal use thereof | PTPN7, PTPN1, PTPN5 | FFAR1 868/4885ALOX5 3048/4885HRH3 840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.